<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
TAK
Takeda
$
()


  • FDA approvesTakeda's Eohilia for eosinophilic esophagitis treatment

    2/12/2024 - 08:05am
  • Takeda to rapidly initiate the first global Phase 3 trials of TAK-861

    2/8/2024 - 18:02pm
  • Takeda announces CFO Costa Saroukos to leave, Milano Furuta to succeed

    2/1/2024 - 05:43am
  • Protagonist Therapeutics, Takeda enter into license agreement for Rusfertide

    1/31/2024 - 18:41pm
  • Halozyme announces Takeda received EC approval for HYQVIA

    1/29/2024 - 16:30pm
  • Takeda's Gammagard Liquid approved by FDA for new indication

    1/29/2024 - 11:12am
  • Takeda announces EC approval of Hyqvia

    1/29/2024 - 05:18am
  • Guggenheim ups CymaBay price target to $28, sees M&A potential

    1/25/2024 - 09:25am
  • Halozyme: Takeda receives FDA approval of HYQVIA co-formulated with ENHANZE

    1/16/2024 - 08:17am
  • FDA approves Takeda's HYQVIA to treat CIDP as maintenance therapy

    1/16/2024 - 08:06am
  • Takeda announces China NMPA Approval of LIVTENCITY in CMV

    12/21/2023 - 16:01pm
  • Takeda announces CHMP opinion recommending approval of Hyqvia

    12/15/2023 - 08:19am
  • Takeda says FDA approves ADZYNMA

    11/9/2023 - 15:55pm
  • FDA approves Takeda's Adzynma for rare inherited blood clotting disorder

    11/9/2023 - 14:44pm
  • Takeda gets FDA approval of Fruzaqla for previously treated colorectal cancer

    11/8/2023 - 17:56pm
dynamic_feed Breaking News